Partnership goals to incorporate Aclarion’s Nociscan surgical decisioning expertise inside ATEC’s AlphaInformatiX platform to raised inform spine surgical procedure
ATEC is a medical system firm devoted to revolutionizing the method to spine surgical procedure via medical distinction
Aclarion’s Nociscan is the primary augmented intelligence platform to measure disc well being biomarkers within the lumbar spine to assist physicians determine the situation of power low again ache
BROOMFIELD, CO, Oct. 23, 2023 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of power low again ache, introduced as we speak that the Firm has executed a non-binding Letter of Intent (“LOI”) to kind a strategic partnership with ATEC Backbone, Inc., the wholly owned working subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).
Uniting the distinctive structural knowledge powered by ATEC’s AlphaInformatiX, with the modern biomarker knowledge that allows Aclarion’s Nociscan answer to determine every disc as painful or not, will present surgeons with unprecedented knowledge throughout one platform. The platform is designed to enhance medical outcomes whereas lowering total procedural prices for sufferers with power again ache.
Pat Miles, CEO of ATEC, commented, “Evolving spinal applied sciences via innovation requires self-discipline, time, know-how, and assets. This partnership with Aclarion displays our perception within the significance of biochemical markers inside the therapy paradigm. Nociscan is strictly the kind of innovation that may advance our shared objective of integrating and advancing applied sciences that enhance the predictability and reproducibility of spine care.”
Aclarion’s proprietary decision-support software, Nociscan, is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to focus on if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
Aclarion’s printed trials affirm the comparative benefit of Nociscan in attaining differentiated surgical outcomes. In April 2023, Aclarion introduced a printed, peer-reviewed, 85% success fee at 2 years for discogenic low again ache surgical procedures for sufferers whose therapy technique was in keeping with Nociscan-identified discs. This outcome was a 22-percentage level enchancment over sufferers whose therapy technique was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).1
“We share a standard imaginative and prescient with ATEC relating to the worth of superior resolution help info to enhance affected person care. This strategic partnership is a major milestone for Aclarion. Pat and the ATEC crew are revolutionizing spine surgical procedure, and we admire their endorsement,” stated Brent Ness, CEO of Aclarion.
The LOI contemplates a multi-step strategic partnership. Below the LOI, ATEC and Aclarion will work collectively to determine Key Opinion Chief (KOL) surgeons to judge Nociscan expertise. Suggestions from these surgeons will inform medical evaluations designed to evaluate the utility of Nociscan at the side of EOS imaging, the inspiration of ATEC’s AlphaInformatiX platform. Assuming constructive synergies, ATEC and Aclarion will co-market Nociscan in focused markets. In alternate for choose entry to ATEC’s surgeon community for the analysis and development of Nociscan, Aclarion will present ATEC with sure unique distribution rights to incorporate Nociscan as a part of an built-in procedural answer.
Persistent low again ache (cLBP) is a world healthcare downside with roughly 266 million individuals worldwide affected by degenerative spine illness and low again ache. Typical imaging and diagnostics present precious structural info however are restricted in figuring out the supply of the pathogenic ache.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra info, please go to www.aclarion.com.
Alphatec Holdings, Inc., via its wholly owned subsidiaries, Alphatec Backbone, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical system firm devoted to revolutionizing the method to spine surgical procedure via medical distinction. ATEC’s Natural Innovation MachineTM is concentrated on growing new approaches that combine seamlessly with the Firm’s increasing AlphaInformatiX Platform to raised inform surgical procedure and extra safely and reproducibly obtain the targets of spine surgical procedure. ATEC’s imaginative and prescient is to be the Normal Bearer in Backbone. For extra info, go to us at www.atecspine.com.
This press launch incorporates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, resembling “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Trade Fee. Readers are inspired to overview the part titled “Threat Elements” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
The knowledge acknowledged above was ready by Aclarion and displays solely the opinion of Aclarion. Nothing on this assertion shall be construed to indicate any help or endorsement of Aclarion or any of its merchandise by ATEC.
Kirin M. Smith
PCG Advisory, Inc.